Clinical impact of genomic analysis in children with B-acute
lymphoblastic leukemia: A pilot study in Slovakia

J 2019

Clinical impact of genomic analysis in children with B-acute lymphoblastic leukemia: A pilot study in Slovakia

VASKA, A., M. MAKOHUSOVA, Karla PLEVOVÁ, K. SKALICKA, M. CERMAK et. al.

Basic information

Original name

Clinical impact of genomic analysis in children with B-acute lymphoblastic leukemia: A pilot study in Slovakia

Authors

VASKA, A. (703 Slovakia), M. MAKOHUSOVA (703 Slovakia), Karla PLEVOVÁ (203 Czech Republic, guarantor, belonging to the institution), K. SKALICKA (703 Slovakia), M. CERMAK (703 Slovakia), F. CHOVANEC (703 Slovakia), O. FABRI (703 Slovakia), P. SVEC (703 Slovakia) and A. KOLENOVA (703 Slovakia)

Edition

Neoplasma, Bratislava, Slovenská akademie vied, 2019, 0028-2685

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Slovakia

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 1.721

RIV identification code

RIV/00216224:14110/19:00112733

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.4149/neo_2019_190328N274

UT WoS

000499649200017

Keywords in English

children acute lymphoblastic leukemia; B-other; genetic markers; SNP-array

Abstract

V originále

Acute lymphoblastic leukemia (ALL) belongs to a genetically heterogeneous disease associated with a wide range of chromosomal and molecular changes. Determining these changes at the time of diagnosis can help the therapeutic decision, and contributes to the prediction of patients' clinical outcomes. A part of B-ALL (B-other) lacks cytogenetic abnormalities with clinical relevance for prognosis. Our first goal was to retrospectively review genetic results of patients from 2013-2017 and identify number of B-other patients in Slovak population. The second goal was to implement single nucleotide polymorphism (SNP) array analysis to improve the diagnosis and risk stratification. In this study we reviewed 133 B-ALL patients. We found that nearly 40% of them (52 cases) belonged to the B-other ALL group. Eighteen B-other ALL patients were subjected to the analysis using SNP-array. Overall, we identified 126 cytogenomic changes and in 4 patients the SNP array revealed clinically relevant markers of adverse prognosis and high relapse risk. Integrating identified genetic changes into clinical practice can bring improvement of prognosis assessment for children with ALL in Slovakia.

Links

EF16_013/0001818, research and development project

Name: Modernizace a podpora výzkumných aktivit národní infrastruktury pro translační medicínu EATRIS-CZ

Citovat

VASKA, A., M. MAKOHUSOVA, Karla PLEVOVÁ, K. SKALICKA, M. CERMAK, F. CHOVANEC, O. FABRI, P. SVEC and A. KOLENOVA. Clinical impact of genomic analysis in children with B-acute lymphoblastic leukemia: A pilot study in Slovakia. Neoplasma. Bratislava: Slovenská akademie vied, 2019, vol. 66, No 6, p. 1009-1018. ISSN 0028-2685. Available from: https://dx.doi.org/10.4149/neo_2019_190328N274.

@article{1609499,
   author = {Vaska, A. and Makohusova, M. and Plevová, Karla and Skalicka, K. and Cermak, M. and Chovanec, F. and Fabri, O. and Svec, P. and Kolenova, A.},
   article_location = {Bratislava},
   article_number = {6},
   doi = {http://dx.doi.org/10.4149/neo_2019_190328N274},
   keywords = {children acute lymphoblastic leukemia; B-other; genetic markers; SNP-array},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {Clinical impact of genomic analysis in children with B-acute lymphoblastic leukemia: A pilot study in Slovakia},
   url = {http://dx.doi.org/10.4149/neo_2019_190328N274},
   volume = {66},
   year = {2019}
}

TY  - JOUR
ID  - 1609499
AU  - Vaska, A. - Makohusova, M. - Plevová, Karla - Skalicka, K. - Cermak, M. - Chovanec, F. - Fabri, O. - Svec, P. - Kolenova, A.
PY  - 2019
TI  - Clinical impact of genomic analysis in children with B-acute lymphoblastic leukemia: A pilot study in Slovakia
JF  - Neoplasma
VL  - 66
IS  - 6
SP  - 1009-1018
EP  - 1009-1018
PB  - Slovenská akademie vied
SN  - 00282685
KW  - children acute lymphoblastic leukemia
KW  - B-other
KW  - genetic markers
KW  - SNP-array
UR  - http://dx.doi.org/10.4149/neo_2019_190328N274
L2  - http://dx.doi.org/10.4149/neo_2019_190328N274
N2  - Acute lymphoblastic leukemia (ALL) belongs to a genetically heterogeneous disease associated with a wide range of chromosomal and molecular changes. Determining these changes at the time of diagnosis can help the therapeutic decision, and contributes to the prediction of patients' clinical outcomes. A part of B-ALL (B-other) lacks cytogenetic abnormalities with clinical relevance for prognosis. Our first goal was to retrospectively review genetic results of patients from 2013-2017 and identify number of B-other patients in Slovak population. The second goal was to implement single nucleotide polymorphism (SNP) array analysis to improve the diagnosis and risk stratification. In this study we reviewed 133 B-ALL patients. We found that nearly 40% of them (52 cases) belonged to the B-other ALL group. Eighteen B-other ALL patients were subjected to the analysis using SNP-array. Overall, we identified 126 cytogenomic changes and in 4 patients the SNP array revealed clinically relevant markers of adverse prognosis and high relapse risk. Integrating identified genetic changes into clinical practice can bring improvement of prognosis assessment for children with ALL in Slovakia.
ER  -

VASKA, A., M. MAKOHUSOVA, Karla PLEVOVÁ, K. SKALICKA, M. CERMAK, F. CHOVANEC, O. FABRI, P. SVEC and A. KOLENOVA. Clinical impact of genomic analysis in children with B-acute lymphoblastic leukemia: A pilot study in Slovakia. \textit{Neoplasma}. Bratislava: Slovenská akademie vied, 2019, vol.~66, No~6, p.~1009-1018. ISSN~0028-2685. Available from: https://dx.doi.org/10.4149/neo\_{}2019\_{}190328N274.

Detailed Information on Publication Record